[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635542":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":23,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":9,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Amisulpride",null,"Receiving amisulpride (5mg) as postoperative prophylactic antiemetic drugs",[13],"Drug: Tropisetron",{"label":15,"type":10,"description":16,"interventionNames":10},"Tropisetron","receiving tropisetron (2mg) as postoperative prophylactic antiemetic drugs",[18],{"type":19,"name":15,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","and receive tropisetron (2mg) as a postoperative prophylactic antiemetic",[9],[9],{"type":24,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100635542","amisulpride-for-the-prevention-of-postoperative-nausea-and-vomiting-in-patients-undergoing-laparoscopic-surgery-100635542",false,"NCT07554040","Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery","Amisulpride Used for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery: a Prospective Observational Cohort Study","Inclusion Criteria:\n\n* 1\\. 18\\\u003CBMI≤30kg\u002Fm2 2. Patients scheduled to undergo gynecological laparoscopic surgery (e.g., ovary, fallopian tube, uterus, and gynecological tumors, etc., with an expected surgery duration of ≤3 hours)\n\nExclusion Criteria:\n\n* 1\\. ASA class IV or above 2. Long-term use of opioid drugs or non-steroidal anti-inflammatory drugs 3. Undergoing radiotherapy and chemotherapy 4.Allergic to the medication used 5.Pregnant or breastfeeding women 6.Previously existing vestibular disorders or chronic dizziness, easily nauseous 7.Recent use of antiemetic drugs or prophylactic antiemetic regimen (within 7 days before surgery) 8.Presence of neurological or psychiatric disorders, or cognitive impairment","FEMALE","18 Years","75 Years",{"count":36,"type":37},526,"ESTIMATED","OBSERVATIONAL","This study aims to focus on patients undergoing gynecological laparoscopic surgery and further evaluate the role of amisulpride in preventing postoperative nausea and vomiting in these patients.",[41],"PONV","NOT_YET_RECRUITING","2026-04-21",{"date":45,"type":46},"2026-04-28","ACTUAL",{"date":48,"type":37},"2026-05-10",{"date":50,"type":37},"2026-12-10",{"name":5,"class":6}]